Bristol Myers Squibb (BMY) Short-Term Debt issuances (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Short-Term Debt issuances data on file, last reported at $321.0 million in Q1 2026.

• Quarterly Short-Term Debt issuances fell 12.77% year-over-year to $321.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$47.0 million (up 98.13% YoY) and the FY2024 annual result came in at $99.0 million, up 182.5% from the prior year.
• Short-Term Debt issuances grew to $321.0 million in Q1 2026 per BMY's latest filing, from -$431.0 million in the prior quarter.
• Across five years, Short-Term Debt issuances topped out at $3.0 billion in Q1 2024 and bottomed at -$2.6 billion in Q2 2024.
• The 5-year median for Short-Term Debt issuances is $42.0 million (2022), against an average of $17.6 million.
• Peak annual rise in Short-Term Debt issuances reached 2233.59% in 2024, while the deepest fall reached 2341.74% in 2024.
• Tracing BMY's Short-Term Debt issuances over 5 years: stood at -$58.0 million in 2022, then tumbled by 508.62% to -$353.0 million in 2023, then retreated by 14.73% to -$405.0 million in 2024, then declined by 6.42% to -$431.0 million in 2025, then jumped by 174.48% to $321.0 million in 2026.
• Per Business Quant, the three latest BMY Short-Term Debt issuances figures stand at $321.0 million (Q1 2026), -$431.0 million (Q4 2025), and $431.0 million (Q3 2025).

Peer Comparison